SELLAS Life Sciences Group, Inc. SLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
1.8
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$26.9M | — | — | $70.9M |
| 2024 | — | -$30.9M | — | — | $9.5M |
| 2023 | $0 | -$37.3M | — | — | -$8.0M |
| 2022 | $1.0M | -$41.3M | — | — | $4.9M |
| 2021 | $7.6M | -$20.7M | — | — | $20.3M |
| 2020 | $1.9M | -$16.8M | — | — | $28.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.8 (grey)
- Working capital / assets 0.87
- Retained earnings / assets -3.51
- EBIT / assets -0.361
- Equity / liabilities 9.482
Source: SEC EDGAR filings · CIK 0001390478 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.